...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pain research & management: the journal of the Canadian Pain Society = journal de la socie?te? canadienne pour le traitement de la douleur >Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
【24h】

Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia

机译：肉毒杆菌毒素型A患者治疗成本特发性三叉神经痛的疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To assess the therapeutic efficacy and safety of botulinum toxin type A (BTX-A) for treating idiopathic trigeminal neuralgia (ITN) in patients ≥80 years old. Methods. Selected patients n=43 with ITN, recruited from the neurology clinic and inpatient department of the Second Affiliated Hospital of Soochow University between August 2008 and February 2014, were grouped by age, one subset n=14 ≥80 years old and another n=29 <60 years old. Each group scored similarly in degrees of pain registered by the visual analogue scale (VAS). Dosing, efficacy, and safety of BTX-A injections were compared by group. Results. Mean dosages of BTX-A were 91.3?±?25.6?U and 71.8?±?33.1?U in older and younger patients, respectively t=1.930,?p=0.061. The median of the VAS score in older patients at baseline (8.5) declined significantly at 1 month after treatment (4.5) p=0.007, as did that of younger patients (8.0 and 5.0, resp.) p=0.001. The median of the D values of the VAS scores did not differ significantly by group (older, 2.5; younger, 0; Z=?1.073, p=0.283). Two patients in each group developed minor transient side effects p=0.825. Adverse reactions in both groups were mild, resolving spontaneously within 3 weeks. Conclusions. BTX-A is effective and safe in treating patients of advanced age (≥80 years old) with ITN, at dosages comparable to those used in much younger counterparts (<60 years old).
机译：客观的。评估肉毒杆菌毒素型（BTX-A）的治疗疗效和安全性，用于治疗≥80岁患者的特发性三叉神经痛（ITN）。方法。从2008年8月和2014年2月之间从苏蒙大学第二附属医院的神经内科和住院部门招募了患者N = 43，按年龄分组，一个子集N = 14岁甚至，另一个= 29岁<60岁。每组在视觉模拟量表（VAS）注册的疼痛程度上相似地评分。 BTX-A注射剂的给药，疗效和安全性被组进行比较。结果。平均剂量为BTX-A为91.3？±25.6？U和71.8？±33.1？u？你在较旧的患者中，分别为t = 1.930，？p = 0.061。在治疗后1个月（8.5）的基线（8.5）的老年患者的VAS评分中位数下降（4.5）P = 0.007，如年轻患者（8.0和5.0，ARCH。）p = 0.001。 VAS分数的D值的中值并没有显着差异（较大的，2.5;年轻，0; Z =？1.073，P = 0.283）。每组两名患者开发了次要瞬态副作用P = 0.825。两组的不良反应温和，在3周内自发地分解。结论。 BTX-A在治疗高龄（≥80岁）的患者中是有效和安全的，其剂量与较年轻的同行（<60岁）相当的剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号